Evidence map›Paper›PMID 32495515›Full record

ArticleHIV medicine2020

Clinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care.

C C Iwuji, M Shahmanesh, O Koole, K Herbst, D Pillay, M J Siedner, K Baisley, H-DREAM Network

Abstract read
In one paragraph

Article in HIV medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

C C IwujiDepartment of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK.ORCID 0000-0003-2045-1717
M ShahmaneshAfrica Health Research Institute, KwaZulu-Natal, South Africa.
O KooleAfrica Health Research Institute, KwaZulu-Natal, South Africa.
K HerbstAfrica Health Research Institute, KwaZulu-Natal, South Africa.
D PillayAfrica Health Research Institute, KwaZulu-Natal, South Africa.
M J SiednerAfrica Health Research Institute, KwaZulu-Natal, South Africa.
K BaisleyAfrica Health Research Institute, KwaZulu-Natal, South Africa.ORCID 0000-0003-1849-6625
H-DREAM Network

Funding

Maximizing combination HIV prevention, uptake and retention by adolescent girls and young womenR01MH114560 · NIMH · KWAZULU-NATAL RESEARCH INSTITUTE TB-HIV · PI SHAHMANESH, MARYAM · 2017 to 2023
$2.0M
NIMH NIH HHS R01 MH114560Wellcome TrustWellcome Trust 201433/Z/16/Z
6 · The paper itself

Abstract

introductionThere is limited literature on the appropriateness of viral load (VL) monitoring and management of detectable VL in public health settings in rural South Africa.

methodsWe analysed data captured in the electronic patient register from HIV-positive patients ≥ 15 years old initiating antiretroviral therapy (ART) in 17 public sector clinics in rural KwaZulu-Natal, during 2010-2016. We estimated the completion rate for VL monitoring at 6, 12, and 24 months. We described the cascade of care for those with any VL measurement ≥ 1000 HIV-1 RNA copies/mL after ≥ 20 weeks on ART, including the following proportions: (1) repeat VL within 6 months; (2) re-suppressed; (3) switched to second-line regimen.

resultsThere were 29 384 individuals who initiated ART during the period [69% female, median age 31 years (interquartile range 25-39)]. Of those in care at 6, 12, and 24 months, 40.7% (9861/24 199), 34% (7765/22 807), and 25.5% (4334/16 965) had a VL test at each recommended time-point, respectively. The VL results were documented at all recommended time-points for 12% (2730/22 807) and 6.2% (1054/16 965) of ART-treated patients for 12 and 24 months, respectively. Only 391 (18.3%) of 2135 individuals with VL ≥ 1000 copies/mL on first-line ART had a repeat VL documenting re-suppression or were appropriately changed to second-line with persistent failure. Completion of the treatment failure cascade occurred a median of 338 days after failure was detected.

conclusionWe found suboptimal VL monitoring and poor responses to virologic failure in public-sector ART clinics in rural South Arica. Implications include increased likelihood of morbidity and transmission of drug-resistant HIV.

Indexed as

Drug Resistance, ViralAdultAnti-HIV AgentsElectronic Health RecordsFemaleHIV InfectionsHumansMalePractice Guidelines as TopicRural PopulationSouth AfricaTreatment FailureViral LoadAnti-HIV Agentsantiretroviral therapyHIV drug resistanceSouth Africaviral load monitoringvirological failure

Identifiers

PMID32495515
PMCPMC7384088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.